Magnolia Tejas

Magnolia Tejas Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company is a subsidiary of Magnolia Neurosciences Corporation, which launched in 2018 with a $31 million Series A investment by Accelerator Life Science Partners and was co-founded by world-class researchers at The University of Texas MD Anderson Cancer Center. Magnolia Tejas received a grant of nearly $20 million from the Cancer Prevention and Research Institute of Texas. The company endeavors to make life-changing medicines for the benefit of patients and their families suffering from neurological side effects from chemotherapy. The company’s offices are located in Houston, Texas on the JLabs campus at the Texas Medical Center.